Status:
COMPLETED
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
Lead Sponsor:
Kenneth R. Phelps, M.D.
Collaborating Sponsors:
Genzyme, a Sanofi Company
Conditions:
Hyperparathyroidism
Chronic Kidney Disease
Eligibility:
All Genders
18-120 years
Phase:
PHASE3
Brief Summary
The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium reabsorption in the distal nephron and thereby necessitates supranormal \[PTH\]to maintain normocalcemia in ...
Detailed Description
The parathyroid hormone concentration (\[PTH)\] rises as glomerular filtration rate (GFR) falls. This almost universal phenomenon is called secondary hyperparathyroidism (SHPT). \[PTH\] rises with die...
Eligibility Criteria
Inclusion
- eGFR \< 60 ml/min
- age at least 18 years
Exclusion
- any primary parathyroid disease
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01191762
Start Date
April 1 2010
End Date
April 1 2013
Last Update
November 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stratton Veterans Affairs Medical Center
Albany, New York, United States, 12208